Bristol-Myers Squibb Co vs General Dynamics Corporation — how do they compare? Bristol-Myers Squibb Co trades at $63.41 (market cap $132.45B), while General Dynamics Corporation trades at $391.11 (market cap $107.13B). The key difference: Bristol-Myers Squibb Co is the larger of the two by market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.89%). Which is the better fit depends on your goals.
| BMY | GD | |
|---|---|---|
Market Cap | $132.45B | $107.13B |
Sector | Health | Industrials |
52-Week High | $65.89 | $395.97 |
52-Week Low | $42.60 | $312.53 |
Enterprise Value | $166.44B | $112.28B |
Dividend Yield | 3.89% | 1.61% |
Trailing returns across standard periods
Latest headlines on both assets
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →